Navigation Links
SAPPHIRE trial shows long-term benefit of carotid stenting as alternative to surgery
Date:4/10/2008

Washington, D.C. (April 10, 2008) Carotid artery stenting is an effective option for high risk patients who are not eligible for surgery, according to a long-term study published in this weeks New England Journal of Medicine. Carotid artery disease, which involves clogging of the arteries in the neck that provide blood to the brain, is a significant risk factor for stroke, making these study results important for the estimated 200,000 Americans each year who would otherwise not be candidates for the treatment.

The SAPPHIRE trial showed patients undergoing carotid stenting were comparably protected from stroke, heart attack, death, and repeat revascularization procedures as patients who underwent the traditional surgical approach (endarterectomy). SAPPHIRE is the first and longest (three years) randomized study to compare the safety and efficacy of carotid stenting with embolic protection to surgery in high risk patients. High risk patients are considered to be at increased risk for surgery because of prior carotid artery surgery, radiation to the neck, chronic heart failure, lung disease or severe coronary artery disease, among other criteria.

The Society for Cardiovascular Angiography and Interventions (SCAI), the worlds leading society of interventional cardiologists, is encouraged by these positive data. Results are consistent with one-year SAPPHIRE data and echo conclusions from other non-randomized trials supporting the use of carotid stenting, particularly in patients with multiple illnesses.

This is more good news for patients who otherwise might not have treatment options, said Dr. Bonnie Weiner, president of the Society for Cardiovascular Angiography and Interventions. Carotid artery stenting is an effective, safe way to help patients avoid debilitating and potentially fatal strokes. We are hopeful that this news will help pave the way for expanded use of this procedure.

Carotid Artery Stenting

Carotid artery stenting is a non-surgical, percutaneous procedure in which a small plastic tube called a catheter is inserted through an artery in the leg and threaded to the blockage in the neck. A thin wire (guidewire), which has a collapsible umbrella-like filter device attached to its end, is advanced passed the blockage. The umbrella is opened and acts as a filter to the blood flowing to the brain, preventing particles from passing to the brain and causing stroke while opening up the blockage and inserting a tiny mesh tube called a stent. The blocked artery is then dilated by inflating a balloon, which pushes the plaque in the artery against its walls and makes way for the stent, which is inserted to prop open the artery. Once the stent is in place, the umbrella filter is removed.

SAPPHIRE

SAPPHIRE, a multi-center, prospective, randomized study, evaluated the safety and performance of the Cordis PRECISE® Nitinol Stent and AngioGuard® Emboli Capture Guidewire, compared with surgery, in 334 patients with carotid artery stenosis. The pre-specified major secondary endpoint at three years was a composite of death, stroke, or myocardial infarction within 30 days after the procedure or death or ipsilateral stroke (occurring on the same side) between 31 days and three years.

At three years, data were available for 260 patients, 85.6 percent of patients (143 of 167) in the stenting group and 70.1 percent of patients (117 of 167) in the surgery group. The pre-specified major secondary endpoint occurred in 41 of the 167 patients who underwent stenting (cumulative incidence, 24.6 percent) and in 45 of 167 patients who underwent endarterectomy (cumulative incidence, 26.9 percent). There was no statistical significance between these groups. Target-vessel revascularization (a procedure to re-open the blocked arteries) was infrequent in both groups.

Although this report is specific to the products mentioned above, it is consistent with results from registries using other similar devices. This supports the overall role of carotid stenting in this patient population.


'/>"/>

Contact: Kathy Boyd David
kbdavid@scai.org
712-422-1181
Society for Cardiovascular Angiography and Interventions
Source:Eurekalert

Related medicine news :

1. OrbusNeich Receives CE Mark Approval for Sapphire(TM) 1.25MM PTCA Dilatation Catheter
2. Stopping a cancer trial early: is it for the benefit of patients or industry?
3. Syndicoms Collaborative Web Platform Chosen to Facilitate Clinical Trials for Lumbar Disc Device from Aesculap Implant Systems
4. Surgeons announce advance in atrial fibrillation surgery
5. Clinical trial volunteers mostly indifferent -- but not blind to -- researchers financial conflicts
6. Clinical trial will test new HIV/AIDS vaccine
7. Knowing doctors financial interests doesnt deter clinical trial participants
8. Report Claims Clinical Trials Miss Many Populations
9. Renal artery stenting falls short in large randomized trial
10. Cystic Fibrosis Foundation announces positive early results for phase 2 clinical trial of VX-770
11. Some Cancer Trials Overstate Findings, Analysis Claims
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 24, 2017 , ... Learn to use popular ... or even in relationships. Course offered by Dr. Carol Francis at PVNET on ... limited seating and the many hands-on experiences. , Dr. Carol Francis shows ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... that its annual Solutions Series of webinars will start January 31 with a ... a number of current health and benefits topics, including employee engagement, pricing transparency, ...
(Date:1/24/2017)... ... January 24, 2017 , ... Bellus Medical, a leader in medical ... experts. In his new role Dr. Dobke will provide physician oversight for in-house clinical ... the Head of Plastic Surgery and Associate Professor of Surgery at UC San Diego ...
(Date:1/24/2017)... N.C. (PRWEB) , ... January 24, 2017 , ... ... Administration is the focus of a new report from the Frank Hawkins ... Business School. , Influential business leaders, academics and policy makers identified concrete solutions ...
(Date:1/24/2017)... ... January 24, 2017 , ... The results from the ... everyone and particularly good news for prostate cancer patients: incidents of cancer is down ... to the report the cancer death rate has dropped from its peak of 215.1 ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... 2017 Sherpa Clinical Packaging ( www.sherpaclinical.com ... is pleased to announce the appointment of Kevin Rosenthal as ... Sherpa team to lead Sherpa,s Operations group and ... excellence. Kevin is not new to ... He has extensive experience working for leading pharma ...
(Date:1/24/2017)... and PUNE, India , January 24, 2017 ... Allied Market Research, titled, "Acidity Regulators Market - Global ... for acidity regulators was valued at $4,456 million in 2015, and ... CAGR of 7.96% from 2016 to 2022. Asia-Pacific ... maintain its lead, followed by North America ...
(Date:1/24/2017)... , January 24, 2017 ... value of USD 3.8 billion by 2025, according to ... market growth can be attributed to the rising initiatives ... early diagnosis of micro calcifications in breast tissue. Some ... CDC, and Breast Cancer Organization are promoting the early ...
Breaking Medicine Technology: